Prospective, Non-interventional, Observational Study for Multi-dimensional Assessment of Signs, Symptoms, Quality of Life and Disease Control of Long-term Treatment With Dupilumab in Patients With Atopic Dermatitis (≥6 Years)
Latest Information Update: 14 Jul 2025
At a glance
- Drugs Dupilumab (Primary)
- Indications Atopic dermatitis
- Focus Therapeutic Use
- Acronyms PROTYPE2
- Sponsors Sanofi
Most Recent Events
- 03 Jul 2025 Planned End Date changed from 8 Mar 2027 to 8 Mar 2028.
- 03 Jul 2025 Planned primary completion date changed from 5 Mar 2025 to 8 Mar 2028.
- 18 Sep 2023 New trial record